HCSG — Q3 2026 Financial Report Analysis

Profit fell 42%, but only because last year had a tax-credit windfall

Healthcare Services Group runs the housekeeping, laundry and kitchen departments of about 2,700 nursing homes, senior living communities, hospitals and campuses across the US, mostly by taking over the facility's own staff and managing them. In the third quarter of 2026 (July–September), revenue rose 3.3% to $479.6 million, while net income fell 42.1% to $24.9 million and diluted earnings per share fell from $0.59 to $0.36.

The drop is a comparison problem, not a business problem. A year ago the company booked a $34.2 million cut to its costs, plus $5.3 million of interest income, when the IRS paid out Employee Retention Credits (ERC) — a pandemic-era payroll tax credit for 2020–2021 wages. Nothing like that happened this quarter. Strip out the one-off items in both years and the underlying business earned noticeably more than a year ago, with both of its segments widening their margins.

The numbers

*The company doesn't report an operating income line; this is revenue minus costs of services and selling, general and administrative (SG&A) expense, as a share of revenue. Last year's 9.9% includes the $34.2 million ERC benefit.

For the first nine months, revenue was $1,413.2 million (+3.1%) and net income $73.6 million, against $27.8 million a year earlier, when results carried $63.9 million of bad-debt expense from the bankruptcy of Genesis Healthcare, one of its largest customers.

What drove the quarter

Both segments got more profitable. "Segment margin" here is the profit each service line keeps from its revenue after its own labor, food and supplies, bad debts and local overhead. Environmental Services rose to 13.3% from 10.7%, and Dietary to 8.7% from 5.1%. The filing's cost breakdown shows where:

• Dietary food and supply costs fell to 30.1% of segment revenue from 31.3%, and labor to 59.1% from 59.6%.
• Environmental Services supplies fell to 7.0% of revenue from 7.5%; labor was flat at 78.6% versus 78.5%.
• Bad debts turned into a credit. Bad-debt expense was −1.3% of Environmental Services revenue (versus +0.9% a year ago) and −0.3% of Dietary revenue (versus +1.5%). Across both segments it swung from a $5.6 million charge to a $3.6 million credit, mostly because of the Genesis recovery below.

Management says tariff and trade-policy changes have not had a material effect so far, because those costs are generally passed through to customers.

Head-office costs rose a little once you remove investment noise. Reported SG&A fell 4.1% to $48.5 million, but that line includes the swing in a deferred-compensation fund held for employees (a $0.7 million loss this year versus a $3.7 million gain last year, which is offset elsewhere in the income statement). Excluding it, SG&A rose 4.9% to $49.1 million, "driven primarily by increased professional fees primarily associated with our merger and acquisition activity." That is 10.2% of revenue, inside the company's 9.5–10.5% target range.

Genesis bankruptcy: first money expected back. Genesis Healthcare filed for Chapter 11 in July 2025 owing HCSG $50.4 million in receivables and $20.4 million in notes, which the company reserved 100% as uncollectable. On October 14, 2026 the bankruptcy court approved Genesis's plan; a $150 million litigation settlement and the sale of Genesis's assets left about $250 million for unsecured creditors, which the filing says "far surpassed the Debtors' previous estimates." HCSG therefore reduced its reserve by $6.1 million this quarter, an estimate of what it now expects to recover.

What the headline numbers hide

• One-offs point in opposite directions in each year. Last year's quarter was inflated by $34.2 million of ERC credits in costs and $5.3 million of ERC interest income. This year's was helped by the $6.1 million Genesis recovery. Removing them — and the deferred-compensation swings, which roughly cancel between SG&A and other income — pre-tax income was about $27.6 million this quarter versus about $17.8 million a year ago, by our calculation from the filing's figures. On that basis, operating margin was about 5.2% versus 3.3%. The −42% headline understates how the business actually did.
• Smaller reserve releases than last year. Updates to workers' compensation and general liability loss estimates cut costs by $1.8 million this quarter versus $3.1 million a year ago — a small tailwind in both years, slightly smaller this time.
• Buybacks did some of the per-share work. The company bought back 0.6 million shares for $12.7 million in the quarter and 2.7 million for $57.0 million year to date. Diluted shares fell 4.9%, which is why EPS fell less (−39.0%) than net income (−42.1%). About 7.7 million shares remain authorized.
• Cash conversion is fine once timing is removed. Third-quarter operating cash flow was $30.2 million, but $9.5 million of that came from a higher payroll accrual (wages owed but not yet paid at quarter-end), so the company's own adjusted figure is $20.7 million — below the $24.9 million net income, partly because the $6.1 million Genesis recovery is a non-cash gain. Year to date, operating cash flow of $95.8 million compares with net income of $73.6 million, but $23.8 million of that is the same payroll accrual building up.
• Receivables are growing faster than sales. Net accounts receivable rose to $309.6 million from $281.3 million at the end of 2025 (+10.1%), while nine-month revenue grew 3.1%; receivables and notes absorbed $41.5 million of cash this year. Long-term notes receivable — money customers owe on longer repayment terms — also climbed to $42.4 million from $25.2 million. For a company whose customers depend on Medicare and Medicaid payments, and which just lived through a major customer's bankruptcy, this is the line to watch.
• More possible one-time gains are still on the table. The company still carries a $12.3 million deferred ERC liability — refunds already received for the third quarter of 2021 that it will only book as income once it's reasonably sure it qualified. The earnings release also says there is "a substantially higher potential upper-range recovery" on Genesis. Either could flatter future quarters in the same way ERC flattered last year's.

Takeaway: The 42% profit decline is last year's $34.2 million tax-credit windfall dropping out, not a weaker business. Adjusting both years for one-offs, pre-tax income rose from roughly $17.8 million to $27.6 million, and both service lines widened their margins on lower food and supply costs — the real question now is whether receivables, up 10% against 3% sales growth, start to eat into that.

Outlook

Management guided fourth-quarter revenue to $535–545 million and raised its 2027 revenue growth outlook from mid-single digits to low double digits. CEO Ted Wahl described "the organic growth inflection we planned for." The NEXDINE Hospitality deal — dining and hospitality management, including senior living, bought for $93.5 million in cash plus possible performance-based payments — is expected to add "over $150 million in annual revenue at comparable margins" and be immediately accretive to earnings, according to the release.

Our read: a full quarter of NEXDINE at that run rate is a bit over $37 million, and it was owned for all but the first five days of the fourth quarter. Prorated, that covers roughly 55–65% of the $55–65 million gap between this quarter's revenue and the Q4 guide, so the guidance also needs about $20–30 million more from the existing business — a 4–6% step-up in a single quarter, faster than the 3.3% it grew over the past year. Other targets to hold management to: costs of services "in the 86% range" (83.2% this quarter, flattered by the Genesis credit) and a full-year tax rate of about 25%.

What to watch next quarter:

• Organic growth. Whether revenue lands in the $535–545 million range, and how much of it the company attributes to existing clients versus NEXDINE.
• The balance sheet after the deal. Cash and marketable securities were $204.3 million at September 30 with nothing drawn on a $300 million credit line (extended to 2031 in April); the $93.5 million purchase takes that to roughly $111 million, part of which is restricted in the company's captive insurer.
• Receivables and Genesis. Whether receivables growth slows, and whether further Genesis recoveries arrive — useful cash, but one-offs that shouldn't be mistaken for operating improvement.